RNA vaccines possess significant clinical promise in counteracting human diseases caused
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …

Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic
acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from …

Lipid nanoparticles (LNPs) are the prime delivery vehicle for mRNA vaccines. Previous
hypotheses suggested that LNPs contribute to innate reactogenicity and lead to the …

To be effective, RNA vaccines require both in situ translation and the induction of an immune
response to recruit cells to the site of immunization. These factors can pull in opposite …

The recent clinical success of multiple mRNA-based SARS-CoV-2 vaccines has proven the
potential of RNA formulated in lipid nanoparticles (LNPs) in humans, and products based on …

Although the tremendous progress has been made for mRNA delivery based on classical
cationic carriers, the excess cationic charge density of lipids was necessary to compress …

Lipid nanoparticle (LNP) formulated messenger RNA-based (LNP-mRNA) vaccines came
into the spotlight as the first vaccines against SARS-CoV-2 virus to be applied worldwide …

Self-amplifying RNA (SAM) represents a versatile tool that can be used to develop potent
vaccines, potentially able to elicit strong antigen-specific humoral and cellular-mediated …

Nucleic acid-based vaccines such as viral vectors, plasmid DNA, and mRNA are being
developed as a means to address a number of unmet medical needs that current vaccine …

Nucleic acid vaccination relies on injecting DNA or RNA coding antigen (s) to induce a
protective immune response. RNA vaccination is being increasingly used in preclinical and …